The company's share price Relmada Therapeutics
Relmada is a biotech company focused on treating depression. Its stock price chart is a dramatic story of the promise of its lead drug, followed by a stock collapse after a key clinical trial failure.
Relmada is a biotech company focused on treating depression. Its stock price chart is a dramatic story of the promise of its lead drug, followed by a stock collapse after a key clinical trial failure.
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly depression. We've categorized it as a "Neurology" company. The chart below shows how investors view the mental health sector.
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly depression. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the neuroscience sector.
For Relmada Therapeutics, Inc., a company focused on depression treatment, daily price change is a measure of its enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment formulas.
Relmada Therapeutics, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with RLMD, a depression-focused stock, helps to assess it as a high-risk asset.
Relmada Therapeutics is a biotech company specializing in the treatment of central nervous system disorders, including depression. Its shares are driven by news of clinical trials. This high volatility is a significant component of the overall "noise" and stock market dynamics.
Relmada Therapeutics' year-to-date performance is a story about the development of a new drug for the treatment of depression. Its 12-month market cap depends entirely on the results of key Phase III clinical trials. Success could offer patients a new mechanism of action, but failure in this complex area would deal a serious blow to its valuation.
Relmada Therapeutics, Inc. is a late-stage biotech developing drugs for the treatment of depression. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and enormous potential for success in this complex field.
Relmada is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its depression drug trials. The company's stock chart lives in a world of its own.
Relmada Therapeutics is a biopharmaceutical company focused on CNS diseases. Its monthly performance is entirely dependent on the results of its clinical trials, particularly its lead drug for depression. These trials are binary outcome events.
Relmada Therapeutics is focused on developing drugs for the treatment of central nervous system disorders, particularly major depressive disorder. The chart below reflects the overall sentiment in the neuroscience sector, where the need for new, effective antidepressants is enormous.
Relmada Therapeutics is a biotech company focused on treating depression. Its stock is a bet on the success of its key drug in clinical trials. Its price action is binary (success/failure) and completely unrelated to the broader stock market.
Shares of Relmada, a biopharmaceutical company developing drugs to treat depression, are experiencing high volatility on a weekly basis. News about the progress of its key clinical trials and FDA decisions could dramatically change the company's value in a short period of time.
Relmada shares, like those of the entire mental health biotech sector, are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Relmada shares, like those of the entire mental health biotech sector, are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Relmada's market capitalization chart is the financial valuation of a biotech company developing a new depression drug. It reflects both the high hopes for this huge market and the disappointment of unsuccessful clinical trials. Its volatile dynamics tell the story of the challenges of creating a successful drug for central nervous system disorders.
Relmada Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system disorders, with a particular focus on depression. Its sector share reflects the market's confidence in its lead candidate. The chart below is a barometer of market confidence in this new approach to depression treatment.
Relmada Therapeutics develops new drugs for the treatment of central nervous system disorders, including depression. The chart below shows the overall market capitalization of the entire sector. Its dynamics reflect the enormous need for more effective antidepressants. Relmada is betting on a new mechanism of action.
Depression treatment is a huge market, as the chart shows. Relmada Therapeutics is developing a new antidepressant with potentially faster action and fewer side effects. Its capitalization is a risky bet that its drug could become a new standard in psychiatry.
Relmada's book value represents capital for a breakthrough in depression treatment. Currently in the R&D stage, the company is using its financial assets for late-stage clinical trials of its lead drug, which could become a new class of antidepressants.
Relmada Therapeutics, a late-stage biopharmaceutical company, focuses on CNS diseases. Its stake in the sector is minimal. The company uses an outsourced manufacturing and clinical trials model, focusing on development management.
Relmada Therapeutics is a late-stage biotech, which makes its model still relatively "light." Its value lies in the clinical trial data of its depression drug. Compared to the pharmaceutical sector, its balance sheet doesn't yet reflect the "heaviness" of its commercial infrastructure.
Relmada's assets are not in older antidepressants, but in the development of a new class of drugs for the treatment of severe depression that target NMDA receptors. The company's balance sheet reflects the value of this decades-long research effort. The chart shows the capital invested in the search for breakthroughs in psychiatry.
Relmada Therapeutics is a biopharmaceutical company focused on treating central nervous system disorders. Its market value is highly volatile, reflecting investor hopes and disappointments regarding the clinical trial results of its lead drug.
Relmada Therapeutics is a biotech company developing drugs for the treatment of central nervous system disorders. Its market valuation is a bet on the success of its lead candidate. This chart shows the vast gap between this hope and its minimal tangible assets.
Relmada Therapeutics is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases. Its market capitalization is based on the potential of its scientific research. This chart demonstrates how much a biotech company's valuation can exceed its book value thanks to the strength of its intellectual property.
Relmada Therapeutics focuses on developing drugs for the treatment of central nervous system diseases. Clinical trials in this area are particularly complex and lengthy. Debt financing is a way for the company to ensure the continuity of its key research programs.
Relmada Therapeutics is a late-stage biopharmaceutical company specializing in central nervous system disorders, such as depression. Funding large-scale Phase 3 trials is a huge challenge. This chart shows how the company is using capital to complete its key trials, which will shape its future.
Relmada Therapeutics, which is developing drugs to treat depression, is in expensive clinical trials. This chart shows its dependence on external funding. Developing drugs for the central nervous system is a long and risky process. Their high debt is a bet that their drug will be more effective than existing analogues.
Relmada Therapeutics develops drugs to treat central nervous system disorders, primarily major depressive disorder. This chart compares the debt it raised to fund large-scale clinical trials to the total market capitalization of the entire neuroscience sector. It illustrates the financial side of the fight against mental disorders.
Relmada Therapeutics is a biopharmaceutical company focused on diseases of the central nervous system. Conducting late-stage clinical trials requires hundreds of millions of dollars. The chart shows how the company manages its capital to fund these key studies, allowing it to assess its financial risks before potential market entry.
This chart for Relmada Therapeutics, a company developing drugs to treat depression, is a story of high hopes and disappointments. Investors' assessment of its potential profits hinges heavily on their belief that its drugs will prove effective in late-stage trials. The dynamics reflect these risky bets.
This chart reflects the average valuation for the speculative biotech sector—the benchmark for Relmada. Comparison with this metric clearly demonstrates how disappointed investors are in the company's developments following the unsuccessful clinical trials. A valuation significantly below average indicates deep market skepticism.
Relmada Therapeutics is a biotech company focused on developing drugs to treat central nervous system disorders, particularly depression. This is a huge market, but also an area with a high risk of clinical trial failure. This chart shows the market's risk appetite, allowing investors to understand how they view the company's scientific data and its chances of success in this complex therapeutic area.
Relmada Therapeutics is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, with a primary focus on depression. This chart reflects analyst expectations for its key drug candidate. It essentially represents a bet on the success of its clinical trials and potential approval.
%20P%2FE%20Relmada%20Therapeutics&width=1500&height=450&colorIndex=35&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Relmada-Therapeutics "Chart of the company's future (projected) P/E Relmada Therapeutics")
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, particularly depression. This chart compares its future revenue expectations with the biotech sector. It demonstrates how the market views its lead candidate and its potential to become a new treatment option for patients.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=36&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment "Future (projected) P/E graph of the market segment -")
Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on drugs for the treatment of central nervous system diseases. This chart shows the company's overall risk appetite. RLMD's success depends solely on clinical trial results. A positive market environment helps attract capital, but cannot replace strong scientific data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole "Chart of the future (projected) P/E of the market as a whole")
Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for central nervous system disorders, primarily depression. This chart shows the company's financial trajectory based on research. Current results reflect the costs of conducting large clinical trials.
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly major depressive disorder. This chart shows overall profitability in the neuroscience sector, reflecting the enormous need for new, more effective treatments for mental disorders.
Relmada Therapeutics is a biopharmaceutical company focused on diseases of the central nervous system. Its success depends on the results of clinical trials of its lead drug for the treatment of depression. The demand for such drugs is non-cyclical. However, investor sentiment in the biotech sector depends on the overall market situation.
Relmada Therapeutics is a biopharmaceutical company focused on developing a new drug for the treatment of severe depression. This is a huge market with a significant unmet need. This chart reflects analyst expectations regarding the results of key clinical trials and the potential success of the drug.
%20profit%20of%20the%20company%20Relmada%20Therapeutics&width=1500&height=450&colorIndex=41&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Relmada-Therapeutics "Graph of future (projected) profit of the company Relmada Therapeutics")
Relmada Therapeutics is a biopharmaceutical company developing new treatments for diseases of the central nervous system, with a focus on major depressive disorder. This chart shows forecasts for the biotech sector. Relmada's future profitability depends on the success of its lead candidate, which may offer a new mechanism of action for patients who are unresponsive to existing therapies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20&width=1500&height=450&colorIndex=42&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment "Graph of future (predicted) profits of companies in a market segment -")
Relmada Therapeutics is a company developing drugs for the treatment of central nervous system diseases. Like many biotech companies, it depends on clinical trial results and access to funding. This chart, illustrating overall profit expectations, highlights the investment climate, which affects funding for long-term research and development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole "Chart of future (predicted) profits of the market as a whole")
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly depression. This chart shows that the company's valuation is based on expectations, reflecting the huge potential market for this new, effective antidepressant.
Relmada Therapeutics is a biopharmaceutical company specializing in central nervous system (CNS) diseases, with a lead candidate for the treatment of major depressive disorder. This chart reflects the average biotech valuation, helping to understand how highly investors view Relmada's potential for treating one of the most common CNS conditions.
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly depression. This revenue valuation indicator emphasizes that investors are not assessing current sales, but rather the hope of developing a new, effective antidepressant.
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly depression. This chart reflects investor expectations for the future success of its lead drug. The valuation is based on the enormous potential revenue if approved.
%20P%2FS%20Relmada%20Therapeutics&width=1500&height=450&colorIndex=47&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Relmada-Therapeutics "The graph of the company's future (projected) P/S Relmada Therapeutics")
Relmada Therapeutics is a biopharmaceutical company developing a new drug for the treatment of major depressive disorder. This chart compares the company's future revenue expectations with its industry. It reflects the enormous investor anticipation of a potential blockbuster in one of the largest fields in medicine.
%20P%2FS%20market%20segment%20graph%20-%20&width=1500&height=450&colorIndex=48&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph "Future (projected) P/S market segment graph -")
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. This chart reflects confidence in future growth, and Relmada is working on a new generation of antidepressants. The success of its developments could radically change approaches to depression treatment and create a huge market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole "Chart of the future (projected) P/S of the market as a whole")
Relmada Therapeutics is a late-stage clinical development biopharmaceutical company specializing in diseases of the central nervous system. Currently, the company has no commercial sales revenue. Any revenue reflected in this chart is likely related to licensing agreements.
Relmada Therapeutics is a clinical-stage biopharmaceutical company developing new drugs for the treatment of central nervous system disorders, primarily depression. This graph reflects the enormous need for new and effective antidepressants, as existing treatments do not work for everyone.
Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on diseases of the central nervous system. Its operations require significant investment. The growth in overall economic activity, reflected in this chart, creates a more favorable environment for raising capital, allowing companies like Relmada to fund their long-term research programs.
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, with a key candidate for the treatment of major depressive disorder. This chart reflects analyst expectations for the results of the decisive clinical trials of this potential blockbuster.
%20sales%20of%20the%20company%20Relmada%20Therapeutics&width=1500&height=450&colorIndex=53&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Relmada-Therapeutics "Schedule of future (projected) sales of the company Relmada Therapeutics")
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly major depressive disorder. This chart shows forecasts for the neuroscience sector, illustrating the enormous need for new, more effective, and safer antidepressants.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=54&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment "Schedule of future (projected) sales of companies in the market segment -")
Relmada Therapeutics, which focuses on treating central nervous system disorders, sees this chart as a marker of the stability of the healthcare system. A stable economy, reflected here, ensures predictability in mental health treatment costs, which is important for patient access to new, more effective medications.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole "Schedule of future (predicted) sales of the market as a whole")
Relmada Therapeutics is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, particularly depression. This chart illustrates the cost of medical innovation, showing the company's investment in costly clinical trials.
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly depression. Profitability in this complex field depends on the success of lengthy and expensive clinical trials. The chart demonstrates the company's operational discipline along this path.
Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, particularly major depressive disorder. This graph shows average profitability, and Relmada is trying to solve a huge medical problem. Their success depends on the results of clinical trials of their lead candidate.
Relmada Therapeutics is a biopharmaceutical company focused on diseases of the central nervous system. This graph shows its team of scientists and clinicians. The size of its staff is an indicator of the intensity of its efforts to develop next-generation antidepressants and other CNS drugs.
Relmada Therapeutics is focused on developing new treatments for central nervous system disorders, primarily depression. This chart shows the percentage of neuroscientists in its niche that Relmada attracts. This reflects its scientific potential and commitment to solving one of the most pressing mental health issues.
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its core asset is its team of clinical research specialists. This chart shows the company's activity. This staff increase will be driven by the advancement of its lead candidate through late-stage clinical trials.
Relmada Therapeutics develops drugs to treat diseases of the central nervous system. Biotechnology is an industry with a long development cycle. This chart illustrates the current situation, but for Relmada, successful completion of multi-year clinical trials is far more important, as this will determine its future.
Relmada Therapeutics is an R&D company focused on central nervous system diseases. Its market capitalization reflects investors' hopes for the success of its developments. The very high value on this chart is typical for biotech, where a small team of scientists can create a product worth billions of dollars.
%20of%20the%20company%20Relmada%20Therapeutics%20(RLMD)&width=1500&height=450&colorIndex=63&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Relmada-Therapeutics-RLMD "Chart of market capitalization per employee (in thousands of dollars) of the company Relmada Therapeutics (RLMD)")
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. The company's value is determined by the potential of its lead drug candidate. This chart shows how much investors are betting on the success of this drug, based on the small team developing it.
%20by%20market%20segment%20-%20&width=1500&height=450&colorIndex=64&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment "Market capitalization per employee (in thousands of dollars) by market segment -")
Relmada Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly depression. Its value lies in the potential of its lead candidate. The chart demonstrates the high market valuation of a small team working on a new approach to treating a complex and widespread disease.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market "Market capitalization per employee (in thousands of dollars) for the overall market")
Relmada Therapeutics is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, particularly depression. This is an R&D company. This graph, being negative, represents the investment phase. It reflects how much capital the company is investing in each of its scientists to advance this complex therapy.
%20Chart%20Relmada%20Therapeutics%20(RLMD)&width=1500&height=450&colorIndex=66&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Relmada-Therapeutics-RLMD "Company Profit Per Employee (in thousands of dollars) Chart Relmada Therapeutics (RLMD)")
Relmada Therapeutics (RLMD) is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system (CNS) disorders, particularly depression. Being in the clinical stage, the company incurs high R&D expenses. This chart doesn't show operating profit, but rather the efficiency with which the research team uses capital to advance its research.
%20in%20the%20market%20segment%20-%20&width=1500&height=450&colorIndex=67&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment "Chart of profit per employee (in thousands of dollars) in the market segment -")
Relmada Therapeutics is a biotech company specializing in the treatment of central nervous system (CNS) disorders, particularly depression. This is R&D. This graph will show significant losses per employee, which is typical for the clinical stage. Developing drugs for the CNS is one of the most complex and expensive, which is reflected in the costs of research personnel.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Relmada Therapeutics is a biopharmaceutical company specializing in diseases of the central nervous system. At the clinical trial stage, this graph reflects potential sales, not current sales. Revenue per employee, if any, typically comes from partnerships and is an important indicator of development progress.
&width=1500&height=450&colorIndex=69&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Sales-chart-per-company-employee-Relmada-Therapeutics-RLMD "Sales chart per company employee Relmada Therapeutics (RLMD)")
Relmada Therapeutics is a biotech company specializing in the treatment of central nervous system disorders, particularly depression. This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity required in this complex field of neuroscience to commercialize new antidepressants.
Relmada Therapeutics (RLMD) is a biotech company focused on treating CNS disorders, primarily depression. Their lead candidate is in late-stage development. They are an R&D company. This graph shows the current (zero) commercial return per scientist, pending results.
Relmada Therapeutics is a biopharmaceutical company developing drugs for the treatment of depression. Its lead candidate (REL-1017) has failed several key trials. This chart shows the number of investors betting that the company has no more promising assets and that its lead drug, which they had been betting on, has proven ineffective.
&width=1500&height=450&colorIndex=72&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Relmada-Therapeutics-RLMD "Short Shares Chart for the Company Relmada Therapeutics (RLMD)")
Relmada Therapeutics is working on a new class of antidepressants (targeting NMDA receptors). This chart demonstrates skepticism about this entire niche. Its rise means investors are betting heavily against the entire field of depression drug development, which is known for its extremely high failure rate in Phase III trials.
Relmada Therapeutics is focused on treating depression, developing drugs for the central nervous system. This is a huge market, but with a high risk of trial failure. This chart reflects the general fear. When investors are pessimistic, they fear binary events. A failed Phase III trial could wipe out RLMD's entire value, and during times of fear, this risk seems too great.
Relmada Therapeutics is a biotech focused on treating depression and other central nervous system disorders. The success or failure of trials in this area is a binary event. This chart measures the speed with which investors react to news, showing "overheating" (above 70) on positive data or a drop into "oversold" (below 30) on negative data.
&width=1500&height=450&colorIndex=75&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Relmada-Therapeutics-RLMD "RSI 14 indicator chart for the company's stock Relmada Therapeutics (RLMD)")
Relmada (RLMD) is a "biotech" stock, a "depression hunter." Their specialty is a new mechanism of action (an NMDA antagonist) unrelated to traditional antidepressants. The "Neuro" (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of this entire segment. It's vital to understand: is RLMD's growth due to their R&D, or is the entire biotech sector "overheated?"
Relmada Therapeutics (RLMD) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Relmada Therapeutics is a biotech company developing drugs for the treatment of central nervous system disorders, with a primary focus on major depressive disorder. This chart shows the average 12-month forecast of analysts. It reflects their collective assessment of the likelihood of clinical trial success for their lead candidate.
&width=1500&height=450&colorIndex=78&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RLMD-Relmada-Therapeutics "A chart showing analyst consensus forecasts for the expected stock price. RLMD (Relmada Therapeutics)")
Relmada Therapeutics is a biotech company betting heavily on REL-1017, a candidate drug for severe depression that works through a novel mechanism. This chart shows how far the current stock price differs from the "fair" value predicted by analysts. The gap reflects a binary outcome: failure or blockbuster.
&width=1500&height=450&colorIndex=79&v=mr7eoit3.lf-6of3yf4&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RLMD-Relmada-Therapeutics "A chart showing the difference between the consensus forecast and the actual stock price. RLMD (Relmada Therapeutics)")
Relmada Therapeutics is a biotech company betting all-in on one of the largest markets—depression treatment (MDD). Its success hinges on the approval of a new class of antidepressants. This chart shows analysts' overall expectations across the neuroscience sector, reflecting whether experts believe breakthroughs in the treatment of mental disorders are possible.
Relmada Therapeutics is a biotech company specializing in developing drugs for the treatment of central nervous system disorders, particularly depression. This chart shows the overall risk appetite. For Relmada, which operates in the complex field of psychiatry, overall market optimism is critical to attracting the capital needed to fund lengthy and expensive clinical trials.
Relmada is a clinical-stage biotech with an all-or-nothing focus on mental health. Their entire enterprise is built around a single drug candidate (REL-1017) for major depressive disorder. This chart is a pure R&D barometer. Its dynamics reflect their high-stakes clinical data and the market's (wavering) faith in their only chance.
Relmada Therapeutics (RLMD) is a biopharmaceutical company specializing in CNS diseases. Their primary focus is developing REL-1017 (esmeketamine) as a novel treatment for severe depression. The chart shows the segment average. It helps investors assess how Relmada's risks and potential breakthrough compare to the neuroscience sector average.
Relmada Therapeutics is a biotech company developing new treatments for central nervous system disorders, primarily depression (REL-1017). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this late-stage clinical psychiatry company stacks up against the backdrop of overall economic trends.
